[Elsevier] LANCET Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 ... |
|
This post will be closed automatically in 2026-08-03 18:03
Reward10points
|
post
reply
points
2045
10
Compound Exposure to Extreme Heat and Substantial Landscape Fire-Sourced Air Pollution on Cardiovascular Mortality
10
LANCET Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes
10
Arts education and its role in enhancing cognitive development: A quantitative study of critical thinking and creativity in higher education
10
Perioperative Management of Vitamin K Antagonists and Direct Oral Anticoagulants
20
Uric Acid-to-High-Density Lipoprotein Cholesterol Ratio and Peripheral Arterial Disease: A Cross-Sectional Study from the National Health and Nutrition Examination Survey 1999每2004
